Product Monograph - Kenalog in Orabase 0.1%
ADVERSE REACTIONS
Prolonged administration may elicit the adverse reactions known to occur with systemic steroid preparations; e.g., adrenal suppression, alteration of glucose metabolism, protein catabolism, peptic ulcer activation and others. These are usually reversible and disappear when the hormone is discontinued.
DOSAGE AND ADMINISTRATION
Press a small dab (about 6 mm) to the lesion until a thin film develops. A larger quantity may be required for coverage of some lesions. For optimal results use only enough to coat the lesion with a thin film. Do not rub in. Attempting to spread this preparation may result in a granular, gritty sensation and cause it to crumble. After application, however, a smooth, slippery film develops.
Apply at bedtime to permit steroid contact with the lesion throughout the night. Depending on the severity of symptoms, it may be necessary to apply the preparation 2 or 3 times a day, preferably after meals. If significant regeneration or repair of oral tissues has not occurred in 7 days, additional investigation into the etiology of the oral lesion is advised.
AVAILABILITY OF DOSAGE FORMS
Each gram of KENALOG in ORABASE contains 1 mg (0.1%) of triamcinolone acetonide.
Nonmedicinal ingredients
C Orabase (protective emollient vehicle) contains gelatin, pectin and sodium carboxymethylcellulose.
C Plastibase (plasticized hydrocarbon gel) contains mineral oil and polyethylene.
Tubes of 7.5 g. Keep tightly closed.